Changeflow GovPing Pharma & Drug Safety Heterodimers of Glutamic Acid Patent EP4023624A1
Routine Rule Added Final

Heterodimers of Glutamic Acid Patent EP4023624A1

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4023624A1 by Molecular Insight Pharmaceuticals, Inc. for heterodimers of glutamic acid compounds. The application was published April 1, 2026, with inventors including John W. Babich, Craig N. Zimmerman, and Kevin P. Maresca. The patent designates 24 EU member states for protection.

What changed

The European Patent Office published patent application EP4023624A1 for heterodimers of glutamic acid filed by Molecular Insight Pharmaceuticals, Inc. The application covers pharmaceutical compositions and methods of use, with IPC classifications in C07D, C07C, and A61K therapeutic categories. The publication designates 24 EU member states for potential patent protection.

Pharmaceutical companies and researchers developing glutamic acid-derived therapeutics should review the patent claims for potential licensing needs or design-around strategies. The patent provides Molecular Insight with exclusivity rights in EU markets pending successful national phase validation in each member state.

What to do next

  1. Monitor for national phase entry deadlines
  2. Assess patent validity in target EU markets

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

HETERODIMERS OF GLUTAMIC ACID

Publication EP4023624A1 Kind: A1 Apr 01, 2026

Applicants

Molecular Insight Pharmaceuticals, Inc.

Inventors

BABICH, John W., ZIMMERMAN, Craig N., MARESCA, Kevin P.

IPC Classifications

C07B 59/00 20060101AFI20220530BHEP A61K 51/00 20060101ALI20220530BHEP C07C 275/16 20060101ALI20220530BHEP C07C 275/24 20060101ALI20220530BHEP C07C 275/30 20060101ALI20220530BHEP C07C 311/19 20060101ALI20220530BHEP C07D 213/38 20060101ALI20220530BHEP A61P 35/00 20060101ALI20220530BHEP A61P 21/00 20060101ALI20220530BHEP

Designated States

AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4023624A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Drug development Pharmaceutical manufacturing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!